US Patent

US10525033 — Use of amisulpride as an anti-emetic

Formulation · Assigned to Acacia Pharma Ltd · Expires 2031-03-10 · 5y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a novel injectable formulation of amisulpride in a unit dosage form containing less than 50 mg amisulpride.

USPTO Abstract

Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.

Drugs covered by this patent

Patent Metadata

Patent number
US10525033
Jurisdiction
US
Classification
Formulation
Expires
2031-03-10
Drug substance claim
No
Drug product claim
Yes
Assignee
Acacia Pharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.